BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioAxone Therapeutic Inc. Announces Patients Completed The 6 Week Follow-Up In The Phase I/IIa Trial Of Cethrin(R) For The Treatment Of Acute Spinal Cord Injury


9/19/2006 2:20:20 PM

MONTREAL, Aug. 28 /PRNewswire/ - BioAxone Therapeutic announced today that all patients enrolled in its Phase I/IIa North American clinical trial of Cethrin® for the treatment of acute spinal cord injury (SCI) have completed their 6 week follow-up visit. All essential information has been collected for the clinical trial report that will be available in the fall. Patients will also have additional follow-ups at 3, 6 and 12 months to monitor the progression of the treatment.

"We are pleased to see that Cethrin®'s profile continues to be safe with no drug related adverse events" said Dr. Frank Bobe, President and CEO of BioAxone.

The Cethrin® clinical trials are being conducted in the following cities: Charlottesville, VA. (1 patient); Cincinnati, OH. (3 patients); Montreal, QC. (7 patients); Philadelphia, PA. (5 patients), Phoenix, AZ. (11 patients); Seattle WA. (1 patient); Toronto, ON. (7 patients); Vancouver, BC. (2 patients).

About Cethrin®

Cethrin® has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) in December 2005. Cethrin's® active ingredient, BA-210, is a recombinant protein which acts as a Rho GTPase antagonist to promote neuroprotection and neuroregeneration in the central nervous system (CNS). It has been designed by BioAxone to effectively penetrate into CNS tissue, where it has been clearly shown to elicit the rescue and repair of damaged neurons in BioAxone's preclinical research models.

About BioAxone Therapeutic

BioAxone is a privately owned neuroscience company specializing in the development and commercialization of proprietary technologies that target Rho signaling. Established in April 2000 and headquartered in Montreal, Canada, BioAxone has demonstrated expertise in recombinant protein product development and has a focused small molecule program.

Source: BIOAXONE THERAPEUTIC INC.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES